Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. Beats on EPS, Stock Up 4.8%

Corvus Pharmaceuticals reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 4.8%. However, the lack of revenue figures and guidance leaves uncertainty about future performance. Investors may be cautiously optimistic based on the EPS beat, but further clarity will be needed in future reports.